Pharmacology of cannabinoids

Neuroendocrinology Letters

Volumn 25, Issue 1-2, 2004, Pages 14-23

  Grotenhermen, Franjo ^a  

^a Nova Institut   (Germany)

Author keywords

Cannabinoid receptors; Cannabinoids; Cannabis; Endocannabinoids; Interaction; Marijuana; Pharmacodynamics; Side effects; THC; Therapeutic use

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; DRONABINOL; VANILLOID RECEPTOR; CANNABINOID; ENDOCANNABINOID; PSYCHOTROPIC AGENT; TETRAHYDROCANNABINOL;

ANALGESIA; ANGIOGENESIS; ANTIEMETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRONCHODILATATION; DRUG INHIBITION; FOOD INTAKE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAOCULAR PRESSURE; MEDICAL RESEARCH; MEMORY; MOOD CHANGE; MOTOR COORDINATION; MUSCLE RELAXATION; NEUROPROTECTION; NONHUMAN; REVIEW; SEDATION; ANIMAL; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG POTENTIATION; PHYSIOLOGY;

ANIMALS; CANNABINOIDS; CARDIOVASCULAR PHYSIOLOGY; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; ENDOCANNABINOIDS; HUMANS; PSYCHOTROPIC DRUGS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TETRAHYDROCANNABINOL;

EID: 3242756915     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (148)

1. Loewe S. Cannabiswirkstoffe und Pharmakologie der Cannabinote [(Active constituents of cannabis and pharmacology of the cannabinols.) (In German.)]. Archiv für Experimentelle Pathologie und Pharmakologie 1950; 211:175-93.
2. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38:151-78.
3. Hollister LE. Health aspects of cannabis. Pharmacological Reviews 1986; 38:1-20.
4. ElSohly MA. Chemical constituents of cannabis. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p 27-36.
5. McPartland JM, Russo EB. Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? J Cannabis Ther 2001; 1:103-32.
6. Bueb JL, Lambert DM, Tschirhart EJ. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. Biochim Biophys Acta 2001; 1538:252-9.
7. Hampson A. Cannabinoids as neuroprotectants against ischemia. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p. 101-10.
8. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 1982; 6:245-50.
9. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134:845-52.
10. Costa B, Parolaro D, Colleoni M. Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. Eur J Pharmacol 1996; 313:17-24.
11. Mechoulam R, Hanus L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 2002; 121:35-43.
12. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 1995; 23:825-31.
13. Bornheim LM, Grillo MP. Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem Res Toxicol 1998; 11:1209-16.
14. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76:189-99.
15. Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L. Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 1981; 37:1090-2.
16. Hunt CA, Jones RT, Herning RI, Bachman J. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet Biopharm 1981; 9:245-60.
17. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74:129-80.
18. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002; 68-69:619-31.
19. Pertwee RG. Sites and Mechanisms of Action. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p. 73-88.
20. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A 1999; 96:14228-33.
21. Sanchez C, de Ceballos ML, del Pulgar TG, Rueda D, Corbacho C, Velasco G, et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 2001; 61:5784-9.
22. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60:155-63.
23. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 2000; 14:1432-8.
24. Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur J Pharmacol 2003; 461:27-34.
25. Wiley JL, Martin BR. Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 2002; 121:57-63.
26. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258:1946-9.
27. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001; 298:7-14.
28. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215:89-97.
29. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50:83-90.
30. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001; 98:3662-5.
31. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301:1020-4.
32. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 2002; 99:8400-5.
33. De Petrocellis L, Melck D, Bisogno T, Milone A, Di Marzo V. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience 1999; 92:377-87.
34. Al-Hayani A, Wease KN, Ross RA, Pertwee RG, Davies SN. The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. Neuropharmacology 2001; 41:1000-1005.
35. Di Marzo V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1998; 1392:153-75.
36. Dinh TP, Freund TF, Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 2002; 121:149-58.
37. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76:189-99.
38. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 1999; 96:12198-203.
39. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15:300-2.
40. Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 2001; 415:R5-R7.
41. Izzo AA, Pinto L, Borrelli F, Capasso R, Mascolo N, Capasso F. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 2000; 129:1627-32.
42. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410:822-5.
43. Darmani NA. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav 2001; 69:239-49.
44. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91:1585-614.
45. Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002.
46. Hall W, Solowij N, Lemon J. The health and psychological consequences of cannabis use.. Canberra: Commonwealth Department of Human Services and Health, Monograph Series No. 25; 1994.
47. House of Lords Select Committee on Science and Technology. Cannabis. The scientific and medical evidence. London: The Stationery Office; 1998.
48. Joy JE, Watson SJ, Benson JA, editors. Marijuana and medicine: Assessing the science base. Washington DC: Institute of Medicine, National Academy Press; 1999.
49. Kalant H, Corrigal W, Hall W, Smart R, editors. The health effects of cannabis. Toronto (Canada): Centre for Addiction and Mental Health; 1999.
50. Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998; 59:347-52.
51. Thompson GR, Rosenkrantz H, Schaeppi UH, Braude MC. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol 1973; 25:363-72.
52. Bachs L, Morland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001; 124:200-3.
53. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001; 103:2805-9.
54. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58:909-15.
55. Pope HG Jr. Cannabis, cognition, and residual confounding. JAMA 2002; 287:1123-31.
56. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive Functioning of Long-term Heavy Cannabis Users Seeking Treatment. JAMA 2002; 287:1123-31.
57. Lyketsos CG, Garrett E, Liang KY, Anthony JC. Cannabis use and cognitive decline in persons under 65 years of age. Am J Epidemiol 1999; 149:794-800.
58. Pope HG, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 2003; 69: 303-10.
59. Russo E, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, et al. Chronic cannabis use in the compassionate investigational new drug program: An examination of benefits and adverse effects of legal medical cannabis. J Cannabis Ther 2002; 2:3-57.
60. Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 1998; 20:293-306.
61. Solowij N, Grenyer BFS. Long term effects of cannabis on psyche and cognition. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p. 299-312.
62. Nunez LA, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatr Scand 2002; 105:173-8.
63. Mattes RD, Shaw LM, Engelman K. Effects of cannabinoids (marijuana) on taste intensity and hedonic ratings and salivary flow of adults. Chem Senses 1994; 19:125-40.
64. Freemon FR. Effects of marihuana on sleeping states. JAMA 1972; 220:1364-5.
65. Lissoni P, Resentini M, Mauri R, Esposti D, Esposti G, Rossi D, et al. Effects of tetrahydrocannabinol on melatonin secretion in man. Horm Metab Res 1986; 18:77-8.
66. Hampson RE, Deadwyler SA. Cannabinoids, hippocampal function and memory. Life Sci 1999; 65:715-23.
67. Heyser G, Hampson RE, Deadwyler SA. Effects of delta-9- tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 1993; 264:294-307.
68. Slikker W Jr. Paule MG, Ali SF, Scallet AC, Bailey JR. Behavioral, neurochemical and neurhistochemical effects of chronic marijuana smoke exposure in the nonhuman primate. In: Myrphy L, Bartke A, editors. Marijuana/ Cannabinoids: neurobiology and neurophysiotogy. Boca Raton, FL: CRC Press; 1992. p. 219-73.
69. Müller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 2003; 28:384-8.
70. Pertwee R. In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators. In: Murphy L, Bartke A, editors. Marijuana/Cannabinoids: neurobiology and neurophysiology. Boca Raton, FL: CRC Press; 1992. p. 165-218.
71. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol 2003; 2:291-8.
72. Domino EF. Cannabinoids and the cholinergic system. In: Nahas G, Sutin KM, Harvey DJ, Agurell S, editors. Marihuana and medicine. Totowa, NJ: Humana Press; 1999. p. 223-6.
73. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995; 73:907-10.
74. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Movement Disorders. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p. 205-214.
75. Musty RE, Paul Consroe P. Spastic disorders. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p. 195-204.
76. Lichtman AH, Peart J, Poklis JL, Bridgen DT, Razdan RK, Wilson DM, Poklis A, Meng Y, Byron PR, Martin BR. Pharmacological evaluation of aerosolized cannabinoids in mice. Eur J Pharmacol 2000; 399:141-9.
77. Braida D, Pozzi M, Cavallini R, Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 2001; 104:923-6.
78. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997; 276:2048-50.
79. Wachtel SR, de Wit H Naltrexone does not block the subjective effects of oral delta(9)-tetrahydrocannabinol in humans. Drug Alcohol Depend 2000; 59:251-60.
80. Haney M, Bisaga A, Foltin RW. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berl) 2003; 166:77-85.
81. Mechoulam R, Shohami E. HU-211: Cannabinoid Neuroprotective Agent. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p. 389-400.
82. Grundy RI. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs 2002; 11:1365-74.
83. Van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JF, Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001; 21:6475-9.
84. Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, Biegon A. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med 2002; 30:548-54.
85. Perez-Reyes M. The psychologic and physiologic effects of active cannabinoids. In: Nahas G, Sutin KM, Harvey DJ, Agurell S. Marihuana and medicine. Totowa, NJ: Humana Press; 1999. p. 245-52.
86. Tashkin DP, Levisman JA, Abbasi AS, Shapiro BJ, Ellis NM. Short-term effects of smoked marihuana on left ventricular function in man. Chest 1977; 72:20-6.
87. Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 1975; 18:287-97.
88. Szabo B, Nordheim U, Niederhoffer N. Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther 2001; 297:819-26.
89. Lake KD, Compton DR, Varga K, Martin BR, Kunos G. cannabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 1997; 281: 1030-7.
90. Wagner JA, Varga K, Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med 1998; 76: 824-36.
91. Wagner JA, Jarai Z, Batkai S, Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur J Pharmacol 2001; 423:203-10.
92. Williams CM, Kirkham TC. Observational analysis of feeding induced by Delta(9)-THC and anandamide. Physiol Behav 2002; 76:241-50.
93. Mechoulam R, Shohami E, Fride E, Bab I. The ubiquitous role of endocannabinoids in physiological processes: examples in neuroprotection, feeding and bone formation. First European Workshop on Cannabinoid Research. Madrid (Spain); 2003.
94. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 1998; 95:8375-80.
95. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000; 141:118-26.
96. Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6:313-9.
97. Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989; 249:444-9.
98. McCallum RW, Soykan I, Sridhar KR, Ricci DA, Lange RC, Plankey MW. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999; 13:77-80.
99. Coruzzi G, Adami M, Coppelli G, Frati P, Soldani G. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol 1999; 360:715-8.
100. Pate D. Glaucoma and cannabinoids. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p. 215-24.
101. Laine K, Jarvinen K, Jarvinen T. Topically administered CB(2)-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits. Life Sci 2003; 72:837-42.
102. Murphy L. Hormonal system and reproduction. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p. 289-98,
103. Cabral G. Immune system. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p. 279-88.
104. Melamede R. Possible mechanisms in autoimmune diseases. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p. 111-22.
105. Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 2002; 133: 124-31.
106. Hembree WC 3d, Nahas GG, Zeidenberg P, Huang HF. Changes in human spermatozoa associated with high dose marihuana smoking. Adv Biosci 1978; 22-23:429-39.
107. Chang MC, Berkery D, Schuel R, Laychock SG, Zimmerman AM, Zimmerman S, Schuel H. Evidence for a cannabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction. Mol Reprod Dev 1993; 36:507-16.
108. Zuardi AW, Guimarāes FS, Guimarāes VMC, Del Bel EA. Cannabidiol: Possible therapeutic application. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p. 359-70.
109. Karler R, Turkanis SA. The cannabinoids as potential antiepileptics. J Clin Pharmacol 1981; 21(8-9 Suppl):437S-48S.
110. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986; 30: 277-82.
111. Parker LA, Mechoulam R, Schtievert C. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002; 13:567-70.
112. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000; 97:9561-6.
113. Colasanti BK, Brown RE, Craig CR. Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol. Gen Pharmacol 1984; 15:479-84.
114. Archer RA, Stark P, Lemberger L. Nabilone. In: Mechoulam R, editors. Cannabinoids as therapeutic agents. Boca Raton: CRC Press; 1986. p. 85-103.
115. Burstein S. Therapeutic potential of ajulemic acid (CT3). In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press; 2002. p. 381-8.
116. Fride E, Barg J, Levy R, Saya D, Heldman E, Mechoulam R, Vogel Z. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 1995; 272: 699-707.
117. 9- tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 1997; 46:100-8.
118. 9-tetrahydrocannabinol-tolerant rats. J Neurochem 2000; 74: 1627-35.
119. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 1976; 282: 221-39.
120. Rubino T, Vigano D, Massi P, Parolaro D. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J Neurochem 2000; 75:2080-6.
121. Georgotas A, Zeidenberg P. Observations on the effects of four weeks of heavy marihuana smoking on group interaction and individual behavior. Compr Psychiatry 1979; 20:427-32.
122. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Experimental and Clin Psychopharmacol 1994; 2:244-68.
123. Kleiber D, Soellner R, Tossmann P. Cannabiskonsum in der Bundesrepublik Deutschland: Entwicklungstendenzen, Konsummuster und Einflußfaktoren [(Cannabis consumption in the Federal Republik of Germany: Development tendencies, consumption pattern and influential factors. (In German with English abstract.)]. Bonn: Federal Ministry of Health; 1997.
124. Roques B. Problemes posées par la dangerosité des drogues. Rapport du professeur Bernhard Roques au Secrétaire d'Etat à la Santé [Problems caused by the danger of drugs. Report of professor Bernhard Roques to the Health Minister.) (In French.)]. Paris; 1998.
125. Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol•). J Psychoactive Drugs 1998; 30:187-96.
126. Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J, Salva K, Wiernik PH, Holroyde CP, Hammill S, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 1991; 6(6):352-9
127. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokin 2003; 42(4):327-360.
128. Cichewicz DL, McCarthy EA. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 2003; 304:1010-5.
129. Koe BK, Milne GM, Weissman A, Johnson MR, Melvin LS. Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics. Eur J Pharmacol 1985; 109:201-12.
130. Perez-Reyes M, Burstein SH, White WR, McDonald SA, Hicks RE. Antagonism of marihuana effects by indomethacin in humans. Life Sci 1991; 48:507-15.
131. Bonz A, Laser M, Kullmer S, Kniesch S, Babin-Ebell J, Popp V, Ertl G, Wagner JA. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 2003; 41:657-64.
132. Green K, Kearse EC, McIntyre OL. Interaction between delta-9- tetrahydrocannabinol and indomethacin. Ophthalmic Res 2001; 33:217-20.
133. British Medical Association. Therapeutic uses of cannabis. Amsterdam: Harwood Academic Publishers; 1997.
134. Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine. New Haven: Yale University Press; 1993.
135. Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC Press; 1986.
136. Bagshaw SM, Hagen NA. Medical efficacy of cannabinoids and marijuana: a comprehensive review of the literature. J Palliat Care 2002; 18:111-22.
137. Grotenhermen F. Clinical Pharmacodynamics of Cannabinoids. J Cannabis Ther 2004, in press.
138. Jan TR, Farraj AK, Harkema JR, Kaminski NE. Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice. Toxicol Appl Pharmacol. 2003; 188: 24-35.
139. Chan PC, Sills RC, Braun AG, Haseman JK, Bucher JR. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 1996; 30:109-17.
140. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, Guzman M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003; 111: 43-50.
141. Blazquez C, Casanova ML, Planas A, Del Pulgar TG, Villanueva C, Fernandez-Acenero MJ, Aragones J, Huffman JW, Jorcano JL, Guzman M. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003; 17:529-31.
142. Ralevic V, Kendall DA. Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur J Pharmacol 2001; 418:117-25.
143. Wagner JA, Jarai Z, Batkai S, Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 2001; 423: 203-10.
144. Wagner JA, Hu K, Karcher J, Bauersachs J, Schafer A, Laser M, Han H, Ertl G. CB1 cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction.. Br J Pharmacol 2003, in press.
145. Calignano A, Katona I, Desarnaud F, Giuffrida A, La Rana G, Mackie K, Freund TF, Piomelli D. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 2000; 408:96-101.
146. Carley DW, Paviovic S, Janelidze M, Radulovacki M. Functional role for cannabinoids in respiratory stability during sleep. Sleep 2002; 25:391-8.
147. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418:488-9.
148. Sah P. Never fear, cannabinoids are here. Nature 2002; 418:488-9.